Business Context and Reporting Period
This Form 6-K filing by Belite Bio, Inc. covers the month of December 2025. The report details a significant capital raise event where the Company entered into an underwriting agreement on December 1, 2025, for a public offering of American Depositary Shares (ADSs).
Key Financial Metrics
- Offering Size: 2,272,727 ADSs (each representing one ordinary share).
- Offering Price: $154.00 per ADS.
- Expected Gross Proceeds: Approximately $350.0 million before deducting underwriting discounts, commissions, and offering expenses.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 340,909 additional ADSs at the public offering price.
- Closing Date: Expected on or about December 3, 2025.
Note: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
Material Changes
The primary material change disclosed is the execution of the underwriting agreement for the $350.0 million equity offering. This transaction represents a substantial increase in the Company's capital base pending the closing of the Offering.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on operational outlook, or a detailed discussion of risks and contingencies beyond the standard closing conditions of the Offering. The Offering is subject to the satisfaction of customary closing conditions.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected December 3, 2025) and confirm if the over-allotment option was exercised.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific details on underwriting discounts and commissions to determine net proceeds.
- Confirm the use of proceeds as detailed in the accompanying press release (Exhibit 99.1) and prospectus supplement.
- Check for any subsequent filings regarding the final number of ADSs issued if the over-allotment option is utilized.